Anavex Life Sciences Corp.(AVXL)今日盘中大涨8.32%,引发了投资者广泛关注。
该公司最新阿尔茨海默病候选药物blarcamesine获得欧盟药品监管机构接受上市申请,推动了股价上涨。blarcamesine一旦获批上市,将成为治疗这种常见老年痴呆症的新选择,并填补了现有注射类药物的空白。
与现有产品相比,blarcamesine具有口服给药、无需额外检测和独特的作用机制等优势,可作为现有抗体药物的补充或替代方案,潜在应用前景广阔。再加上Anavex公司目前现金储备充足,可维持约4年的运营,为新药上市销售奠定了坚实基础。综合利好因素,提振了市场对公司长期发展前景的信心,成为股价今日大涨的主因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.